ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)
ASCEND(儿童 ARDS 和 ECMO 启动策略对神经发育的影响)
基本信息
- 批准号:10866863
- 负责人:
- 金额:$ 27.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-05 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAgeAnticoagulationBloodBrainBreathingCannulasChildChild SupportChildhoodClinicalClinical TrialsCommunicationCritically ill childrenDataData CollectionData ElementEquipoiseEvaluationExtracorporeal Membrane OxygenationFailureFamilyFatigueFrequenciesFundingGuidelinesHemorrhageImpairmentInterventionKnowledgeLifeMeasuresMechanical VentilatorsMechanical ventilationMorbidity - disease rateMotorNational Heart, Lung, and Blood InstituteNervous System TraumaNutritional SupportOrgan failureOutcomeOutcome StudyOxygenPatient-Focused OutcomesPediatric Acute Respiratory Distress SyndromePositioning AttributeProne PositionProtocols documentationPump lungQuality of lifeRandomizedRandomized Controlled Clinical TrialsRegistriesSensorySiteStrokeSupinationSupport GroupsTechniquesTestingUncertaintyVentilatorVentilator-induced lung injuryartificial lungblood pumpbody systemcomparative effectiveness studyconventional therapyexperiencefunctional outcomesfunctional statushealth related quality of lifeinstrumentlongitudinal, prospective studymental statemortalityneurodevelopmentpreservationprospectiverandomized, clinical trialsrespiratoryresponsesystematic reviewtreatment as usualventilation
项目摘要
Project Abstract
Decades after extracorporeal membrane oxygenation (ECMO) was first used to support children with severe
pediatric acute respiratory distress syndrome (PARDS), pediatric intensivists lack both prospective studies of
long-term outcomes in ECMO for PARDS and well-powered studies comparing the impact of ECMO initiation
strategies on mortality and morbidity. While clinicians lack the equipoise necessary to randomize ECMO in
dying children, there is uncertainty on if and when it is best to initiate ECMO to preserve survival, functioning,
and quality of life. To answer the question, if and when ECMO should be initiated in children with severe
PARDS, it is necessary to compare the long-term outcomes in ECMO supported children to otherwise similar
children who did not receive ECMO at the same threshold if at all.
An opportunity to address this question is provided by NHLBI-funded Prone and Oscillation Pediatric Clinical
Trial (PROSpect) and the ECMO registry, Extracorporeal Life Support Organization (ELSO). PROSpect is a
randomized clinical trial testing the impact of supine/prone positioning and conventional mechanical
ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in 1,000 children with
severe PARDS. PROSpect manages subjects with a rigorous protocol that reserves ECMO for protocol failure.
The ELSO Registry includes children receiving usual care ECMO, initiated at the discretion of the intensivist.
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development) will harmonize
PROSpect and ELSO data collection and prospectively measure long-term functional status and quality of life
in 550 children with severe PARDS from ELSO sites. ASCEND will then match children in both groups on their
propensity to receive usual care ECMO. ASCEND combines real-world observational data (from ELSO) and a
randomized clinical trial (from PROSpect) by matching similarly critically ill children treated under usual care
ECMO or a rigorous ventilation protocol that reserves ECMO for protocol failure. Our specific aims include:
Aim 1: We will test the hypotheses that one year after children receive usual care ECMO for PARDS, there will
be a decline in long-term functional status and health-related quality of life as well as an increase in the
proportion of children receiving respiratory support.
Aim 2: We will test the hypotheses that 90-day mortality, one-year functional status, and one-year health-
related quality of life are not equivalent for children with usual care ECMO (in ELSO) and PROSpect's
protocolized therapies.
项目摘要
在体外膜氧合(ECMO)首次用于支持重症儿童几十年后
儿科急性呼吸窘迫综合征(PARDS),儿科强化治疗缺乏对
PARDS患者ECMO治疗的长期结果和比较ECMO治疗效果的有效研究
关于死亡率和发病率的战略。虽然临床医生缺乏将ECMO随机化所需的平衡
对于濒临死亡的儿童,是否以及何时启动ECMO以保护生存、功能、
和生活质量。为了回答这个问题,是否以及何时应该对患有重症的儿童启动ECMO
Pards,有必要将ECMO支持的儿童的长期结果与其他相似的儿童进行比较
没有接受ECMO的儿童如果有的话,也是在相同的门槛下接受ECMO。
NHLBI资助的俯卧和振荡儿科临床提供了解决这个问题的机会
试验(PROCESS)和ECMO登记,体外生命支持组织(ELSO)。潜在客户是一种
随机临床试验测试仰卧/俯卧姿势和传统机械姿势的影响
呼吸机/高频振荡呼吸机对1000例慢性阻塞性肺疾病患儿近期和远期临床疗效的影响
严厉的扑克牌。Prospects使用严格的协议管理对象,为协议故障保留ECMO。
ELSO登记处包括接受常规护理的儿童,ECMO是由强化治疗者酌情发起的。
ASCED(儿童ARDS和ECMO启动策略对神经发育的影响)将协调一致
前景和ELSO数据收集和前瞻性测量长期功能状态和生活质量
在550名来自ELSO站点的患有严重Pard的儿童中。然后,Ascend将匹配两个组中的孩子
接受常规护理的倾向ECMO。Ascend结合了真实世界的观测数据(来自ELSO)和一个
随机临床试验(来自PROSPECT),配对在常规护理下接受治疗的类似危重儿童
ECMO或为协议故障保留ECMO的严格通风协议。我们的具体目标包括:
目标1:我们将检验以下假设:在儿童接受帕德的常规护理ECMO一年后,将会有
长期功能状态和与健康相关的生活质量下降,以及
接受呼吸支持的儿童比例。
目标2:我们将测试90天死亡率、一年功能状态和一年健康状况的假设-
接受常规护理的儿童的相关生活质量并不等同于ECMO(ELSO)和Prospects的
原始化疗法。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tracheostomy Practices and Outcomes in Children During Respiratory Extracorporeal Membrane Oxygenation.
- DOI:10.1097/pcc.0000000000002902
- 发表时间:2022-04-01
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Starting and Sustaining an Extracorporeal Membrane Oxygenation Program.
启动并维持体外膜氧合计划。
- DOI:10.1097/mat.0000000000001783
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Dhar,ArchanaV;Morrison,Tracy;Barbaro,RyanP;Buscher,Hergen;Conrad,StevenA;Diaz,Rodrigo;Deng,Joseph;Ellis,WCory;Fortenberry,James;Heard,Micheal;Hyslop,Robert;Miranda,DinisReis;Ogino,Mark;Sin,WaiChingSimon;Zakhary,Bishoy;
- 通讯作者:
Extracorporeal Membrane Oxygenation Then and Now; Broadening Indications and Availability.
体外膜氧合的过去和现在;
- DOI:10.1016/j.ccc.2022.09.003
- 发表时间:2023
- 期刊:
- 影响因子:4.3
- 作者:Pollack,BlytheE;Kirsch,Roxanne;Chapman,Rachel;Hyslop,Robert;MacLaren,Graeme;Barbaro,RyanP
- 通讯作者:Barbaro,RyanP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ryan Barbaro其他文献
Ryan Barbaro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ryan Barbaro', 18)}}的其他基金
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)
ASCEND(儿童 ARDS 和 ECMO 启动策略对神经发育的影响)
- 批准号:
10254392 - 财政年份:2020
- 资助金额:
$ 27.12万 - 项目类别:
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)
ASCEND(儿童 ARDS 和 ECMO 启动策略对神经发育的影响)
- 批准号:
10672336 - 财政年份:2020
- 资助金额:
$ 27.12万 - 项目类别:
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)
ASCEND(儿童 ARDS 和 ECMO 启动策略对神经发育的影响)
- 批准号:
10030654 - 财政年份:2020
- 资助金额:
$ 27.12万 - 项目类别:
ASCEND (ARDS in Children and ECMO initiation strategies impact on Neuro-Development)
ASCEND(儿童 ARDS 和 ECMO 启动策略对神经发育的影响)
- 批准号:
10468145 - 财政年份:2020
- 资助金额:
$ 27.12万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 27.12万 - 项目类别:
Research Grant